Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease
Biomolecules · 2025
DOI: 10.3390/biom15030387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Gorka Larrinaga und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Receptors, G-Protein-Coupled. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza, Basque Government, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Despite advances in the management of advanced clear cell renal cell carcinoma (ccRCC), robust biomarkers for prognosis and therapeutic response prediction remain elusive. Dysregulation of the intrarenal renin–angiotensin system (RAS) has been implicated in renal carcinogenesis but little explored, particularly regarding biomarker discovery and therapeutic innovation. Consequently, this study investigates the immunohistochemical expression and clinical relevance of the Mas-related G-protein-coupled receptor D (MrgD) in patients with ccRCC who developed metastatic disease (mccRCC). A cohort of 132 patients treated between 2008 and 2018 with nephrectomy and tyrosine kinase inhibitor (TKI)-based sequential therapy was analyzed. Treatment response was assessed using both the MASS and RECIST scoring systems. High MrgD expression in primary tumors was significantly associated with larger size, advanced stage, higher histological grade, and worse overall survival. Among 81 patients with metachronous metastases, high MrgD expression independently predicted shorter disease-free survival. High MrgD staining intensity correlated with poorer TKI responses in first-line therapy but improved outcomes with second-line mTORC1 inhibitors. These findings suggest that MrgD may be a useful biomarker of RAS linked to tumor aggressiveness in ccRCC. MrgD holds potential for identifying high-risk patients and guiding treatment selection in advanced disease. Further research is needed to unlock its clinical potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nursing, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
- Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
- Biobizkaia Health Research Institute, 48903 Barakaldo, Spain.
- Pathology Department, Cruces University Hospital, 48903 Barakaldo, Spain.
- Department of Cellular Biology and Histology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain.
- Department of Urology, Cruces University Hospital, 48903 Barakaldo, Spain.
ORCID-Profile: Gorka Larrinaga, Asier Valdivia, David Lecumberri, Ane Miren Iturregui, Charles H Lawrie, María Armesto, Juan F Dorado, Caroline E Nunes-Xavier, Rafael Pulido, José I López, Javier C Angulo
Förderung
- Ekonomiaren Garapen eta Lehiakortasun Saila, Eusko Jaurlaritza
- Basque Government
- Instituto de Salud Carlos III
- European Union
Zitieren
APA
Larrinaga, G., Solano-Iturri, J. D., Arrieta-Aguirre, I., Valdivia, A., Lecumberri, D., Iturregui, A. M., Lawrie, C. H., Armesto, M., Dorado, J. F., Nunes-Xavier, C. E., Pulido, R., López, J. I., & Angulo, J. C. (2025). Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease. Biomolecules. https://doi.org/10.3390/biom15030387
Vancouver
Larrinaga G, Solano-Iturri JD, Arrieta-Aguirre I, Valdivia A, Lecumberri D, Iturregui AM, et al. Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease. Biomolecules. 2025. doi:10.3390/biom15030387
BibTeX
@article{Larrinaga2025,
author = {Larrinaga, Gorka and Solano-Iturri, Jon Danel and Arrieta-Aguirre, Inés and Valdivia, Asier and Lecumberri, David and Iturregui, Ane Miren and Lawrie, Charles H and Armesto, María and Dorado, Juan F and Nunes-Xavier, Caroline E and Pulido, Rafael and López, José I and Angulo, Javier C},
title = {Prognostic and Therapeutic Implications of Alamandine Receptor MrgD Expression in Clear Cell Renal Cell Carcinoma with Development of Metastatic Disease},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15030387}
}
EUVIMED